Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
P/S ratio for Singular Genomics Systems, Inc. (OMIC)
P/S ratio as of 2023: 11.50
According to Singular Genomics Systems, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.50. At the end of 2022 the company had a P/S ratio of 186.94.
P/S ratio history for Singular Genomics Systems, Inc. from 2019 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 11.50 |
| 2022 | 186.94 |
| 2021 | 0.00 |
| 2020 | 0.00 |
| 2019 | 0.00 |